{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:24:41Z","timestamp":1783488281155,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,9,4]],"date-time":"2014-09-04T00:00:00Z","timestamp":1409788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s40618-014-0136-z","type":"journal-article","created":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T00:33:31Z","timestamp":1409704411000},"page":"1041-1048","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["An update on the medical treatment of Graves\u2019 hyperthyroidism"],"prefix":"10.1007","volume":"37","author":[{"given":"Michele","family":"Marin\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Latrofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Menconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Chiovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,4]]},"reference":[{"key":"136_CR1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/thy.2010.0417","volume":"21","author":"RS Bahn Chair","year":"2011","unstructured":"Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21:593\u2013646","journal-title":"Thyroid"},{"key":"136_CR2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jama.1943.02840190008003","volume":"122","author":"EB Astwood","year":"1943","unstructured":"Astwood EB (1943) Treatment of of hyperthyroidism with thiourea and thiouracil. JAMA 122:78","journal-title":"JAMA"},{"key":"136_CR3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","volume":"352","author":"DS Cooper","year":"2005","unstructured":"Cooper DS (2005) Antithyroid drugs. N Engl J Med 352:905\u2013917","journal-title":"N Engl J Med"},{"key":"136_CR4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/thy.1991.1.129","volume":"1","author":"L Wartofsky","year":"1991","unstructured":"Wartofsky L, Glinoer D, Solomon B, Lagasse R (1991) Differences and similarities in the diagnosis and treatment of Graves\u2019 disease in Europe, Japan and the United States. Thyroid 1:129\u2013135","journal-title":"Thyroid"},{"key":"136_CR5","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1210\/jc.2009-2752","volume":"95","author":"AB Emiliano","year":"2010","unstructured":"Emiliano AB, Governale L, Parks M, Cooper DS (2010) Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab 95:2227\u20132233","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/MED.0b013e3283565b49","volume":"19","author":"D Glinoer","year":"2012","unstructured":"Glinoer D, Cooper DS (2012) The propylthiouracil dilemma. Curr Opin Endocrinol Diabet Obes 19:402\u2013407","journal-title":"Curr Opin Endocrinol Diabet Obes"},{"key":"136_CR7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1089\/thy.2009.0169","volume":"19","author":"RS Bahn","year":"2009","unstructured":"Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN (2009) The role of propylthiouracil in the management of Graves\u2019 disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19:673\u2013674","journal-title":"Thyroid"},{"key":"136_CR8","first-page":"1516","volume":"76","author":"D Reinwein","year":"1993","unstructured":"Reinwein D, Benker G, Lazarus JH, Alexander WD (1993) A prospective randomized trial of antithyroid drug dose in Graves\u2019 disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J Clin Endocrinol Metab 76:1516\u20131521","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1507\/endocrj.K10E-262","volume":"58","author":"T Konishi","year":"2011","unstructured":"Konishi T, Okamoto Y, Ueda M, Fukuda Y, Harusato I, Tsukamoto Y, Hamada N (2011) Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves\u2019 disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr J 58:95\u2013100","journal-title":"Endocr J"},{"key":"136_CR10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","volume":"7","author":"P Vitti","year":"1997","unstructured":"Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A (1997) Clinical features of patients with Graves\u2019 disease undergoing remission after antithyroid drug treatment. Thyroid 7:369\u2013375","journal-title":"Thyroid"},{"key":"136_CR11","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1210\/jc.2008-0842","volume":"93","author":"F Kaguelidou","year":"2008","unstructured":"Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, L\u00e9ger J (2008) Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 93:3817\u20133826","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR12","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/jama.1973.03230090011002","volume":"226","author":"L Wartofsky","year":"1973","unstructured":"Wartofsky L (1973) Low remission after therapy for Graves\u2019 disease. Possible relation of dietary iodine with antithyroid therapy results. JAMA 226:1083\u20131088","journal-title":"JAMA"},{"key":"136_CR13","doi-asserted-by":"crossref","first-page":"510","DOI":"10.7326\/0003-4819-107-4-510","volume":"107","author":"BL Solomon","year":"1987","unstructured":"Solomon BL, Evaul JE, Burman KD, Wartofsky L (1987) Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Ann Intern Med 107:510\u2013512","journal-title":"Ann Intern Med"},{"key":"136_CR14","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1210\/jc.2012-4309","volume":"98","author":"G Barbesino","year":"2013","unstructured":"Barbesino G, Tomer Y (2013) Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 98:2247\u20132255","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"136_CR15","first-page":"99","volume":"4","author":"BA Lamberg","year":"1981","unstructured":"Lamberg BA, Salmi J, Wagar G, Makinen T (1981) Spontaneous hypothyroidism after antithyroid treatment of hyperthyroid Graves\u2019 disease. J Endocrinol Invest 4(3):99\u2013402","journal-title":"J Endocrinol Invest"},{"key":"136_CR16","first-page":"98","volume":"78","author":"U Feldt-Rasmussen","year":"1994","unstructured":"Feldt-Rasmussen U, Schleusener H, Carayon P (1994) Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves\u2019 disease. J Clin Endocrinol Metab 78:98\u2013102","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1089\/thy.2008.0121","volume":"18","author":"PF Tripodi","year":"2008","unstructured":"Tripodi PF, Ruggeri RM, Campenn\u00ec A, Cucinotta M, Mirto A, Lo Gullo R, Baldari S, Trimarchi F, Cucinotta D, Russo GT (2008) Central nervous system vasculitis after starting methimazole in a woman with Graves\u2019 disease. Thyroid 18:1011\u20131013","journal-title":"Thyroid"},{"key":"136_CR18","first-page":"531","volume":"36","author":"RM Ruggeri","year":"2013","unstructured":"Ruggeri RM, Imbesi S, Saitta S, Campenn\u00ec A, Cannav\u00f2 S, Trimarchi F, Gangemi S (2013) Chronic idiopathic urticaria and Graves\u2019 disease. J Endocrinol Invest 36:531\u2013536","journal-title":"J Endocrinol Invest"},{"key":"136_CR19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2265.1984.tb03456.x","volume":"21","author":"AP Weetman","year":"1984","unstructured":"Weetman AP, McGregor AM, Hall R (1984) Evidence for an effect of antithyroid drugs on the natural history of Graves\u2019 disease. Clin Endocrinol 21:163\u2013172","journal-title":"Clin Endocrinol"},{"key":"136_CR20","unstructured":"Marcocci C, Marin\u00f2 M (2005) Thyroid directed antibodies. In: Braverman LE, Utiger RD (eds) Werner and Ingbar\u2019s the thyroid: a fundamental and clinical text, 9th edition. Lippincott, Williams & Wilkins, Philadelphia, pp 360\u2013372"},{"key":"136_CR21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0090-1229(83)90186-1","volume":"28","author":"AP Weetman","year":"1983","unstructured":"Weetman AP, McGregor AP, Hall R (1983) Methimazole inhibits thyroid autoantibody production by an action on accessory cells. Clin Immunol Immunopathol 28:39\u201345","journal-title":"Clin Immunol Immunopathol"},{"key":"136_CR22","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1210\/jcem-53-6-1223","volume":"53","author":"I Weiss","year":"1981","unstructured":"Weiss I, Davies TF (1981) Inhibition of immunoglobulin-secreting cells by antithyroid drugs. J Clin Endocrinol Metab 53:1223\u20131228","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1210\/endo-112-1-326","volume":"112","author":"DP Rennie","year":"1983","unstructured":"Rennie DP, McGregor AM, Keast D, Weetman AP, Foord SM, Dieguez C, Williams ED, Hall R (1983) The influence of methimazole on thyroglobulin-induced autoimmune thyroiditis in the rat. Endocrinology 112:326\u2013330","journal-title":"Endocrinology"},{"key":"136_CR24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1210\/jcem-58-1-62","volume":"58","author":"KW Wenzel","year":"1984","unstructured":"Wenzel KW, Lente JR (1984) Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves\u2019 disease: evidence against an immunosuppressive action of thionamide drugs. J Clin Endocrinol Metab 58:62\u201369","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR25","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1210\/jc.2006-2135","volume":"92","author":"H Nakamura","year":"2007","unstructured":"Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N (2007) Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves\u2019 disease. J Clin Endocrinol Metab 92:2157\u20132162","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR26","first-page":"971","volume":"35","author":"D Li","year":"2012","unstructured":"Li D, Pei H, Li X, Liu X, Li X, Xie Y (2012) Short-term effects of combined treatment with potassium bromide and methimazole in patients with Graves\u2019 disease. J Endocrinol Invest 35:971\u2013974","journal-title":"J Endocrinol Invest"},{"key":"136_CR27","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199104043241403","volume":"324","author":"K Hashizume","year":"1991","unstructured":"Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T (1991) Administration of thyroxine in treated Graves\u2019 disease\u2014effects on the level of antibodies to thyroid stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 324:947\u2013953","journal-title":"N Engl J Med"},{"key":"136_CR28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1210\/jcem-57-3-563","volume":"57","author":"JH Romaldini","year":"1983","unstructured":"Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Werner MC, Farah CS, Reis LC (1983) Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab 57:563\u2013570","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR29","first-page":"1481","volume":"80","author":"H Tamai","year":"1995","unstructured":"Tamai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K, Kumagai LF, Nagataki S (1995) Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves\u2019 disease patients. J Clin Endocrinol Metab 80:1481\u20131484","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR30","first-page":"3283","volume":"81","author":"RS Rittmaster","year":"1996","unstructured":"Rittmaster RS, Zwicker H, Abbott EC, Douglas R, Givner ML, Gupta MK, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE (1996) Effect of methimazole with or without exogenous l-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves\u2019 disease. J Clin Endocrinol Metab 81:3283\u20133288","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR31","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7326\/0003-4819-124-7-199604010-00018","volume":"124","author":"A Rizvi","year":"1996","unstructured":"Rizvi A, Crapo LM (1996) Failure of thyroxine therapy for Graves\u2019 disease (letter). Ann Intern Med 124:694","journal-title":"Ann Intern Med"},{"key":"136_CR32","first-page":"814","volume":"83","author":"RS Rittmaster","year":"1998","unstructured":"Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE (1998) Effect of methimazole, with or without l-thyroxine, on remission rates in Graves\u2019 disease. J Clin Endocrinol Metab 83:814\u2013818","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1210\/jcem-40-1-33","volume":"40","author":"CH Emerson","year":"1975","unstructured":"Emerson CH, Anderson AJ, Howard WJ, Utiger RD (1975) Serum thyroxine and triiodothyronine concentrations during iodide treatment of hyperthyroidism. J Clin Endocrinol Metab 40:33\u201336","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bjs.1800720118","volume":"72","author":"JH Marigold","year":"1985","unstructured":"Marigold JH, Morgan AK, Earle DJ, Young AE, Croft DN (1985) Lugol\u2019s iodine: its effect on thyroid blood flow in patients with thyrotoxicosis. Br J Surg 72:45\u201347","journal-title":"Br J Surg"},{"key":"136_CR35","first-page":"1055","volume":"102","author":"DC Chang","year":"1987","unstructured":"Chang DC, Wheeler MH, Woodcock JP, Curley I, Lazarus JR, Fung H, John R, Hall R, McGregor AM (1987) The effect of preoperative Lugol\u2019s iodine on thyroid blood flow in patients with Graves\u2019 hyperthyroidism. Surgery 102:1055\u20131061","journal-title":"Surgery"},{"key":"136_CR36","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1677\/joe.0.1120387","volume":"112","author":"P Laurberg","year":"1987","unstructured":"Laurberg P, Boye N (1987) Inhibitory effect of various radiographic contrast agents on secretion of thyroxine by the dog thyroid and on peripheral and thyroidal deiodination of thyroxine to tri-iodothyronine. J Endocrinol 112:387\u2013390","journal-title":"J Endocrinol"},{"key":"136_CR37","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1530\/acta.0.0680696","volume":"68","author":"LJ DeGroot","year":"1971","unstructured":"DeGroot LJ, Buhler U (1971) Effect of perchlorate and methimazole on iodine metabolism. Acta Endocrinol (Copenh) 68:696\u2013706","journal-title":"Acta Endocrinol (Copenh)"},{"key":"136_CR38","first-page":"453","volume":"2","author":"D Barzilai","year":"1966","unstructured":"Barzilai D, Sheinfeld M (1966) Fatal complications following use of potassium perchlorate in thyrotoxicosis. Report of two cases and a review of the literature. Isr J Med Sci 2:453\u2013456","journal-title":"Isr J Med Sci"},{"key":"136_CR39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1210\/jc.2009-1655","volume":"95","author":"F Bogazzi","year":"2010","unstructured":"Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, Rossi G, Ceccarelli C, Vitti P, Pinchera A, Bartalena L, Martino E (2010) Impact of lithium on efficacy of radioactive iodine therapy for Graves\u2019 disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab 95:201\u2013208","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2265.2012.04385.x","volume":"77","author":"NM Martin","year":"2012","unstructured":"Martin NM, Patel M, Nijher GM, Misra S, Murphy E, Meeran K (2012) Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves\u2019 and toxic nodular disease. Clin Endocrinol (Oxf) 77:621\u2013627","journal-title":"Clin Endocrinol (Oxf)"},{"key":"136_CR41","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000117431","volume":"37","author":"JM Henderson","year":"1997","unstructured":"Henderson JM, Portmann L, Van Melle G, Haller E, Ghika JA (1997) Propranolol as an adjunct therapy for hyperthyroid tremor. Eur Neurol 37:182\u2013185","journal-title":"Eur Neurol"},{"key":"136_CR42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/thy.1991.1.273","volume":"1","author":"WM Wiersinga","year":"1991","unstructured":"Wiersinga WM (1991) Propranolol and thyroid hormone metabolism. Thyroid 1:273\u2013277","journal-title":"Thyroid"},{"key":"136_CR43","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1210\/jc.2010-1935","volume":"96","author":"S Neumann","year":"2011","unstructured":"Neumann S, Eliseeva E, McCoy JG, Napolitano G, Giuliani C, Monaco F, Huang W, Gershengorn MC (2011) A new small-molecule antagonist inhibits Graves\u2019 disease antibody activation of the TSH receptor. J Clin Endocrinol Metab 96:548\u2013554","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2249.2010.04301.x","volume":"163","author":"I Ueki","year":"2011","unstructured":"Ueki I, Abiru N, Kobayashi M, Nakahara M, Ichikawa T, Eguchi K, Nagayama Y (2011) B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves\u2019 hyperthyroidism. Clin Exp Immunol 163:309\u2013317","journal-title":"Clin Exp Immunol"},{"key":"136_CR45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1530\/EJE-08-0084","volume":"159","author":"KA Heemstra","year":"2008","unstructured":"Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TW, Romijn JA, Smit JW (2008) Rituximab in relapsing Graves\u2019 disease, a phase II study. Eur J Endocrinol 159:609\u2013615","journal-title":"Eur J Endocrinol"},{"key":"136_CR46","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W (2011) Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med 364:1920\u20131931","journal-title":"N Engl J Med"},{"key":"136_CR47","first-page":"444","volume":"36","author":"E Piantanida","year":"2013","unstructured":"Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves\u2019 orbitopathy in the XXI century. J Endocrinol Invest 36:444\u2013449","journal-title":"J Endocrinol Invest"},{"key":"136_CR48","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/cen.12185","volume":"79","author":"I B\u00fclow Pedersen","year":"2013","unstructured":"B\u00fclow Pedersen I, Knudsen N, Carl\u00e9 A, Schomburg L, K\u00f6hrle J, J\u00f8rgensen T, Rasmussen LB, Ovesen L, Laurberg P (2013) Serum selenium is low in newly diagnosed Graves\u2019 disease: a population-based study. Clin Endocrinol (Oxf) 79:584\u2013590","journal-title":"Clin Endocrinol (Oxf)"},{"key":"136_CR49","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1089\/thy.2011.0087","volume":"21","author":"A Stagnaro-Green","year":"2011","unstructured":"Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W (2011) Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 21:1081\u20131125","journal-title":"Thyroid"},{"key":"136_CR50","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1210\/jc.2012-2123","volume":"97","author":"JH Lazarus","year":"2012","unstructured":"Lazarus JH (2012) Antithyroid drug treatment in pregnancy. J Clin Endocrinol Metab 97:2289\u20132291","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR51","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1210\/jc.2011-2803","volume":"97","author":"L Groot De","year":"2012","unstructured":"De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, Eastman CJ, Lazarus JH, Luton D, Mandel SJ, Mestman J, Rovet J, Sullivan S (2012) Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:2543\u20132565","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR52","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/jcem-45-6-1187","volume":"45","author":"B Marchant","year":"1977","unstructured":"Marchant B, Brownlie BE, Hart DM, Horton PW, Alexander WD (1977) The placental transfer of propylthiouracil, methimazole and carbimazole. J Clin Endocrinol Metab 45:1187\u20131193","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR53","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1210\/jc.2011-2860","volume":"97","author":"A Yoshihara","year":"2012","unstructured":"Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K (2012) Treatment of Graves\u2019 disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 97:2396\u20132403","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR54","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/02844310310007809","volume":"37","author":"D Ribuffo","year":"2003","unstructured":"Ribuffo D, Costantini M, Gullo P, Houseman ND, Taylor GI (2003) Aplasia cutis congenita of the scalp, the skull, and the dura. Scand J Plast Reconstr Surg Hand Surg 37:176\u2013180","journal-title":"Scand J Plast Reconstr Surg Hand Surg"},{"key":"136_CR55","first-page":"493","volume":"84","author":"F Santini","year":"1999","unstructured":"Santini F, Chiovato L, Ghirri P, Lapi P, Mammoli C, Montanelli L, Scartabelli G, Ceccarini G, Coccoli L, Chopra IJ, Boldrini A, Pinchera A (1999) Serum iodothyronines in the human fetus and the newborn: evidence for an important role of placenta in fetal thyroid hormone homeostasis. J Clin Endocrinol Metab 84:493\u2013498","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR56","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1210\/jc.2008-0966","volume":"93","author":"M Rotondi","year":"2008","unstructured":"Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, Castellano M, Rosei EA, Chiovato L (2008) The effect of pregnancy on subsequent relapse from Graves\u2019 disease following a successful course of anti-thyroid drug therapy. J Clin Endocrinol Metab 93:3985\u20133988","journal-title":"J Clin Endocrinol Metab"},{"key":"136_CR57","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/EJE-10-1030","volume":"164","author":"F Azizi","year":"2011","unstructured":"Azizi F, Amouzegar A (2011) Management of hyperthyroidism during pregnancy and lactation. Eur J Endocrinol 164:871\u2013876","journal-title":"Eur J Endocrinol"},{"key":"136_CR58","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1210\/jcem-57-5-1036","volume":"57","author":"M Zakarija","year":"1983","unstructured":"Zakarija M, McKenzie JM (1983) Pregnancy-associated changes in the thyroid-stimulating antibody of Graves\u2019 disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab 57:1036\u20131040","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0136-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-014-0136-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0136-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T12:12:35Z","timestamp":1565784755000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-014-0136-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,4]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1007\/s40618-014-0136-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,4]]}}}